{"id":"NCT00818662","sponsor":"Baxalta now part of Shire","briefTitle":"A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Two Dose Arm, Parallel Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% (IGIV, 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-12-19","primaryCompletion":"2012-12-10","completion":"2012-12-10","firstPosted":"2009-01-08","resultsPosted":"2014-10-28","lastUpdate":"2021-05-19"},"enrollment":390,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Alzheimer´s Disease"],"interventions":[{"type":"BIOLOGICAL","name":"Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg","otherNames":["Gammagard Liquid","KIOVIG"]},{"type":"BIOLOGICAL","name":"Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg","otherNames":["Gammagard Liquid"]},{"type":"BIOLOGICAL","name":"Placebo solution: Human Albumin 0.25% - 4 mL/kg","otherNames":[]},{"type":"BIOLOGICAL","name":"Placebo solution: Human Albumin 0.25% - 2 mL/kg","otherNames":[]}],"arms":[{"label":"IGIV, 10% 400mg/kg","type":"EXPERIMENTAL"},{"label":"IGIV, 10% 200mg/kg","type":"EXPERIMENTAL"},{"label":"Human Albumin 0.25% Solution - 4 mL/kg","type":"PLACEBO_COMPARATOR"},{"label":"Human Albumin 0.25% Solution - 2 mL/kg","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study was to evaluate the efficacy and safety of 2 doses of Immune Globulin Intravenous (IGIV), 10% administered every 2 weeks as an intravenous (IV) infusion compared with placebo in participants with mild to moderate Alzheimer's disease (AD).","primaryOutcome":{"measure":"Change From Baseline at 18 Months in the Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog)","timeFrame":"Baseline & 18 months","effectByArm":[{"arm":"IGIV, 10% 400mg/kg","deltaMin":7.4,"sd":7.95},{"arm":"IGIV, 10% 200mg/kg","deltaMin":8.9,"sd":8.2},{"arm":"Placebo 2 mL/kg or 4 mL/kg","deltaMin":8.4,"sd":9.37}],"pValues":[{"comp":"OG000 vs OG002","p":"0.476"},{"comp":"OG001 vs OG002","p":"0.530"}]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":3},"locations":{"siteCount":41,"countries":["United States","Canada"]},"refs":{"pmids":["28381506"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":21,"n":127},"commonTop":["Headache","Infusion Site Extravasation","Fall","Diarrhoea","Depression"]}}